Medical Packaging Co SAE

Medical Packaging Co SAE maintains a strong liquidity position, with a current ratio of 7.3, indicating a high ability to meet short-term obligations. The company holds $29.7 million in cash and equivalents, which is a significant portion of its total assets of $189.9 million. The price-to-book ratio of 5.26 and the price-to-tangible-book ratio of 5.26 suggest that the company is trading at a premium relative to its book value.

In terms of profitability, the company's return on equity (ROE) of 5.72% and return on assets (ROA) of 4.88% are below the industry median for the Non-Paper Containers & Packaging sector. The company's net income of $9.3 million represents a net margin of 25.25%, which is relatively high compared to industry peers. However, the company's price-to-earnings ratio of 91.91 is significantly higher than the industry median, indicating that the stock may be overvalued relative to its earnings.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no geographic diversification data available in the provided financials, but the company's operations are likely concentrated in its primary market. This lack of diversification could expose the company to regional economic or regulatory risks.

The company's revenue growth is not explicitly provided in the financial data, but the high price-to-earnings ratio suggests that investors may be anticipating strong future earnings growth. The company's capital expenditure of -$251,900 indicates a reduction in capital spending, which could signal a focus on cost optimization or a slowdown in expansion. The company's free cash flow of $10.3 million suggests that it has sufficient cash flow to support operations and potentially fund future growth initiatives.

The company's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.0 suggests that it is not leveraged and has no long-term debt obligations. The absence of dilution risk is supported by the fact that the number of shares outstanding has not changed between basic and diluted shares.

There are no recent events or filings disclosed in the provided data that would indicate significant changes in the company's operations or financial position. The company's financial statements do not mention any recent regulatory actions, legal proceedings, or strategic initiatives that would impact its future performance.

Revenue grew 37.4% annually over four years, demonstrating strong top-line expansion for the medical packaging company.

Net income surged 73.3% year-over-year, significantly outpacing revenue growth and indicating robust operational leverage.

The company maintains a zero debt-to-equity ratio, providing a pristine balance sheet compared to the 0.36 peer median.

Free cash flow growth stalled at 0.1% year-over-year, failing to keep pace with significant revenue and profit expansion.

Cash conversion ratio of 0.74 falls below the 1.17 industry median, suggesting weaker cash generation efficiency than peers.